Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the fourth quarter and full year ended December 31, 2024.
Quantum-Si’s Customers and Researchers to Showcase Next-Generation Protein Sequencing™ at AGBT 2025
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting February 23-26th.
Quantum-Si and Researchers to Showcase Next-Generation Protein Sequencing™ at US HUPO 2025
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and several distinguished researchers will highlight advances in Next-Generation Protein Sequencing™ (NGPS™) at the US Human Proteome Organization’s 2025 conference in Philadelphia, Pennsylvania through a panel discussion and multiple poster presentations.
Quantum-Si to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 3, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET.
Preprint from Northwestern University Highlights Complementary Proteomic Analysis of Interleukin-6 Using Next-Generation Protein Sequencing™ and Mass Spectrometry
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces a newly released preprint from researchers at Northwestern University, titled "Next-Generation Protein Sequencing and individual ion mass spectrometry enable complementary analysis of interleukin-6." The publication demonstrates the power of combining two cutting-edge technologies, Quantum-Si’s Next-Generation Protein Sequencing™ (NGPS™) on Platinum®, and Individual Ion Mass Spectrometry (I2MS), to achieve a detailed analysis of key regions of the cytokine interleukin-6 (IL-6).
Quantum-Si Establishes Scientific Advisory Board to Shape Next-Generation Proteomic Technologies
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the formation of its Scientific Advisory Board. Comprised of distinguished experts in proteomics, genomics, bioinformatics, chemistry, and engineering, the board will play a critical role in shaping Quantum-Si’s scientific and development strategy, identifying emerging trends and applications, and strengthening engagement within the scientific community.
Quantum-Si and IDEX Health & Science to Partner on Optics Module for Proteus™ Instrument
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and IDEX Health & Science, LLC., today announced they will partner on the development and manufacturing of the optics module for Quantum-Si’s novel proteomics platform, Proteus™.
Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces its participation in the upcoming Festival of Genomics UK, taking place on January 29–30, 2025, at ExCeL London. As part of the event, Richard Broadhead, Ph.D., will deliver a presentation highlighting the latest innovations in Next-Generation Protein Sequencing™ and its transformative impact on proteomics and multiomics research.
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 44,893 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).
Quantum-Si Launches Platinum® Pro: The End-to-End Solution for Deeper Insights in Proteomics
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the launch of Platinum® Pro, its latest benchtop sequencer that sets a new standard in protein analysis. Designed to redefine efficiency and versatility in proteomics research, Platinum Pro is now available for ordering.
Quantum-Si’s New Preprint Showcases Protein Barcoding as a Powerful Tool for Transforming Proteomics
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the release of its latest preprint titled “Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis, and Tracking.” This study highlights the potential of integrating Quantum-Si’s benchtop Platinum® instrument with an innovative protein barcoding workflow, offering a sensitive and accessible approach to multiplexed protein analysis.
Quantum-Si Incorporated Announces Pricing of $50 Million Registered Direct Offering of Common Stock
Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 15,625,000 shares of common stock at a purchase price of $3.20 per share, pursuant to a registered direct offering, resulting in gross proceeds of approximately $50 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about January 6, 2025, subject to the satisfaction of customary closing conditions.
Quantum-Si’s New Preprint Showcases Advances in Protein Variant Detection using ProteoVue™ Software with Next-Generation Protein Sequencing™
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a new paper that was submitted to BioRxiv, demonstrating the capabilities of its proprietary bioinformatics tool called ProteoVue, for detecting and quantifying Single Amino Acid Variants (SAAVs). The paper, titled “Detecting Amino Acid Variants Using Next-Generation Protein Sequencing (NGPS),” highlights the transformative potential of Quantum-Si’s Platinum® benchtop instrument in advancing proteomics research and applications. The full preprint publication will be available soon on the BioRxiv website.
Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 46,666 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).
Quantum-Si Expands International Distribution Network
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announced that it has expanded its international distribution network to a total of 15 partners.
Quantum-Si Launches Platinum® New Library Prep Kit, Expanding Access to Next-Generation Protein Sequencing™
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, has introduced the Platinum Library Prep Kit, V2, an advanced tool for single-molecule protein sequencing that is designed to simplify workflows and expand researchers’ ability to analyze the proteome.
Quantum-Si Introduces Protein Barcoding Kit for Multiplexed Protein Screening
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, has announced the launch of its protein Barcoding Kit designed to transform protein research by empowering researchers with an advanced multiplexed protein screening solution.
Quantum-Si Highlights Major Technical Advances, Next-Generation Platform Architecture and New Proteomic Applications at Investor & Analyst Event
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the highlights of an Investor & Analyst event that was hosted in New York City on November 20th, 2024.
Avantor to Distribute Quantum-Si’s Next-Generation Protein Sequencing™ Technology
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, has announced a distribution agreement with Avantor® (
NYSEAVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries. Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in the U.S. and Canada streamlined access to these innovative proteomics solutions.
Quantum-Si to Develop Acceleration Platform and Advance Core Technologies in Collaboration with NVIDIA
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance Quantum-Si’s core technologies of amino acid binders and aminopeptidases using NVIDIA AI and accelerated computing.
Quantum-Si Expands Collaboration with SkyWater to Develop New Chip Production Process Critical for Groundbreaking New Proteomics Platform
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™ and SkyWaterTechnology (
NASDAQSKYT), the trusted technology realization partner, announced today they will jointly expand their relationship to support development of Proteus™, Quantum-Si’s next-generation platform designed to transform proteomic research. The expanded collaboration will develop the consumable for Proteus that will enable simultaneous large factor, protein sequencing with unparalleled accuracy.
Quantum-Si and Planet Innovation to Partner on Proteus™
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and Planet Innovation today announced that they will partner on the development and manufacturing of Quantum-Si’s novel proteomics platform, Proteus™.
Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 340,460 restricted stock units (“RSUs”) to a new employee under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employee becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).
Quantum-Si Honored with Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Next-Generation Protein Sequencing™
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it has been awarded Frost & Sullivan’s prestigious 2024 Technology Innovation Leadership Award in North America. This award recognizes QSI’s groundbreaking work in developing the Platinum® instrument, the first benchtop sequencer capable of providing single-molecule resolution at the amino acid level, opening new frontiers for proteomic research.
Quantum-Si Reports Third Quarter 2024 Financial Results
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024.
